The increasing prevalence of chronic autoimmune disorders has accelerated demand for targeted biologic therapies that offer long-term disease control and improved patient outcomes. Among these conditions, psoriatic arthritis (PsA) has emerged as a major therapeutic focus due to its progressive nature and significant impact on quality of life. The expansion of the psoriatic arthritis treatment market, continued biologics market growth, and innovations across the autoimmune disease therapeutics market are fueling the rapid development of the Tremfya market.

The global Tremfya market was valued at USD 3.92 billion in 2024 and is projected to grow at a CAGR of 7.4% from 2025 to 2034. The market is expected to reach USD 4.20 billion in 2025 and rise to USD 7.99 billion by 2034.

Growing Demand in the Psoriatic Arthritis Treatment Market

The psoriatic arthritis treatment market continues to expand as awareness, early diagnosis, and access to advanced biologic therapies improve worldwide. Psoriatic arthritis is a chronic inflammatory disease that affects both joints and skin, often causing pain, swelling, stiffness, and progressive joint damage if left untreated.

Current treatment approaches include:

• Biologic therapies
• Disease-modifying antirheumatic drugs (DMARDs)
• Nonsteroidal anti-inflammatory drugs (NSAIDs)
• Corticosteroids
• Targeted synthetic therapies

Among these options, biologic drugs have become the preferred treatment for moderate-to-severe disease because they target specific immune pathways responsible for inflammation rather than suppressing the entire immune system.

The increasing prevalence of psoriasis and psoriatic arthritis, combined with earlier diagnosis and improved treatment guidelines, is significantly driving demand for advanced therapies.

Biologics Market Growth Transforming Autoimmune Care

Strong biologics market growth has transformed the management of autoimmune disorders by offering highly targeted treatments with improved efficacy and safety profiles.

Biologic medicines are produced using living cells and are designed to interfere with specific components of the immune system. They have become the standard of care for several chronic inflammatory diseases, including:

• Psoriasis
• Psoriatic arthritis
• Rheumatoid arthritis
• Crohn's disease
• Ulcerative colitis

IL-23 inhibitors such as Tremfya represent one of the fastest-growing biologic classes because they provide durable symptom control while reducing inflammatory activity. Continuous innovation in monoclonal antibody development is further strengthening the biologics market and expanding therapeutic options for patients.

Autoimmune Disease Therapeutics Market Expands

The autoimmune disease therapeutics market is experiencing robust growth due to rising incidence of immune-mediated disorders, increased healthcare spending, and ongoing pharmaceutical innovation.

Key therapeutic categories include:

• Monoclonal antibodies
• Cytokine inhibitors
• Small-molecule therapies
• Immunomodulators
• Biosimilars

Advances in precision medicine are enabling more personalized treatment strategies, allowing physicians to select therapies based on disease severity, biomarkers, and patient response. These innovations are improving long-term outcomes while reducing disease progression.

Growing investment in clinical research continues to expand the number of available biologic therapies for autoimmune diseases.

Tremfya Market Driving Innovation

The Tremfya market has become one of the fastest-growing segments within autoimmune therapeutics. Tremfya specifically targets the IL-23 p19 subunit, reducing inflammation associated with plaque psoriasis and psoriatic arthritis while preserving other immune functions.

Major factors driving the Tremfya market include:

• Increasing prevalence of plaque psoriasis and psoriatic arthritis
• Strong clinical efficacy and durable treatment response
• Expansion into additional inflammatory bowel disease indications
• Growing physician confidence in IL-23-targeted therapies
• Increasing patient preference for long-acting biologic treatments

The market is also benefiting from expanded regulatory approvals, including newer indications such as ulcerative colitis and Crohn's disease, further broadening its commercial opportunity.

Key Growth Drivers

Several factors continue to support growth across the psoriatic arthritis treatment market, biologics market growth, and autoimmune disease therapeutics market.

Rising Autoimmune Disease Burden

Increasing diagnoses of psoriasis, psoriatic arthritis, and other chronic inflammatory diseases are expanding the patient population requiring long-term treatment.

Continuous Biologic Innovation

Advancements in monoclonal antibody engineering and cytokine-targeted therapies are improving treatment effectiveness and patient outcomes.

Expanding Clinical Indications

Broader regulatory approvals for biologic therapies are increasing their use across multiple autoimmune disorders.

Improved Healthcare Access

Greater availability of specialty care, improved reimbursement policies, and enhanced diagnostic capabilities are supporting wider biologic adoption.

Market Segmentation Overview

The Tremfya market is commonly segmented by application and distribution channel.

By Application

• Plaque psoriasis
• Psoriatic arthritis
• Other approved inflammatory conditions

By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

Plaque psoriasis currently represents the largest application segment, while psoriatic arthritis continues to demonstrate strong growth as physicians increasingly adopt targeted biologic therapies. Hospital pharmacies account for a significant share due to the specialized management and distribution requirements associated with biologic medicines.

Discover the Complete Report Here:

https://www.polarismarketresearch.com/industry-analysis/tremfya-market

Key Players

• Johnson & Johnson

Regional Analysis

North America holds the largest share of the Tremfya market, supported by high biologic adoption rates, advanced healthcare infrastructure, favorable reimbursement systems, and strong awareness of autoimmune diseases.

Europe remains another important market, benefiting from established treatment guidelines and increasing access to innovative biologics. Meanwhile, Asia-Pacific is expected to witness the fastest growth due to improving healthcare infrastructure, expanding biologic availability, rising healthcare expenditure, and increasing diagnosis of chronic inflammatory disorders.

Future Outlook

The future of the psoriatic arthritis treatment market, biologics market growth, and autoimmune disease therapeutics market will be driven by continuous innovation in targeted immunology therapies. Advances in precision medicine, biomarker-guided treatment selection, and next-generation biologics are expected to further improve clinical outcomes.

As research continues to expand therapeutic indications and improve long-term disease management, the Tremfya market is expected to maintain strong growth. Ongoing investment in biologic development and autoimmune disease research will continue to create new opportunities for patients, healthcare providers, and pharmaceutical companies worldwide.

More Trending Latest Reports By Polaris Market Research:

Ankylosing Spondylitis Market

Fertility Supplements Market

aorto-iliac occlusive disease (iliac disease) treatment market

Drug Testing Market

Real World Evidence Solutions Market

North America AI in Medical Imaging Market

Blood-Based Biomarker For Parkinson’s Disease Market

U.S. Remote Patient Monitoring System Market